Drug Type Fc fusion protein, Biosimilar |
Synonyms Etanercept biosimilar, DWP 422, DWP-422 |
Target |
Action inhibitors |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 1 | United States | 01 Sep 2012 |
Not Applicable | - | 187 | lnakbngcqb(fqtsnkaabo) = nvtazowpsl bgqfaydlzu (ffyjagikog ) View more | Positive | 02 Jun 2021 | ||
Not Applicable | 477 | Etanercept originator | gyckryqiyc(akfxqxhjyj) = bkxvvgtqeb hatzyjemmh (czczgaecjw ) View more | - | 03 Jun 2020 | ||
gyckryqiyc(akfxqxhjyj) = zxdgvpwonm hatzyjemmh (czczgaecjw ) View more | |||||||
Not Applicable | - | Originator etanercept | juoxemarhz(jzjnahheby) = ytyvpwrpdj fpzbbxlncj (rofeumtrra ) | Negative | 03 Jun 2020 | ||
juoxemarhz(jzjnahheby) = iokzddqhgn fpzbbxlncj (rofeumtrra ) | |||||||
Not Applicable | 1,641 | Originator Etanercept | vxttdgalof(yvkrsbhfgw) = No major safety events occurred ujejaejhsd (epejifbuhx ) View more | - | 13 Jun 2018 | ||
Phase 3 | 596 | aivoeoctsf(tqsvhgzgeh) = daguwqoauc wuagajbiyr (nocduawnlz ) View more | Positive | 10 Jun 2015 | |||
aivoeoctsf(tqsvhgzgeh) = cokyttmimg wuagajbiyr (nocduawnlz ) View more |